NASDAQ:TBPH | Free Cash Flow | Theravance Biopharma, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2012-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31$73.28M
2025-12-31-$6.06M
2025-03-31$43.04M
2024-12-31-$902,000.00
2024-03-31-$1.02M
2023-12-31-$854,000.00
2023-03-31-$11.22M
2022-12-31-$124.06M
2022-03-31-$26.07M
2021-12-31-$42.43M
2021-03-31-$69.87M
2020-12-31-$64.93M
2020-03-31-$55.1M
2019-12-31-$64.35M
2019-03-31-$81.19M
2018-12-31-$52.18M
2018-03-31$49.83M
2017-12-31-$44.2M
2017-03-31-$50.03M
2016-12-31-$28.11M
2016-03-31-$26.31M$684,000.00-$26.99M
2015-12-31-$33.75M$606,000.00-$34.35M
2015-03-31-$56.51M$657,000.00-$57.17M
2014-12-31-$42.54M$765,000.00-$43.3M
2014-03-31-$44.8M$1.62M-$46.42M
2013-12-31-$35.19M$1.07M-$36.25M
2013-03-31-$28.49M$740,000.00-$29.23M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$238.54M
2024-12-31-$11.54M
2023-12-31-$27M
2022-12-31-$186.99M
2021-12-31-$207.86M
2020-12-31-$250.4M
2019-12-31-$238.2M
2018-12-31-$112.87M
2017-12-31-$201.05M
2016-12-31-$98.99M$2.14M-$101.12M
2015-12-31-$168.86M$2.65M-$171.5M
2014-12-31-$175.16M$3.11M-$178.26M
2013-12-31-$120.96M$2.73M-$123.69M
2012-12-31-$119.11M$2.59M-$121.7M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.